

RECEIVED
CENTRAL FAX CENTER
AUG 21 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. - .16 (Canceled)

17. (Previously Presented) A method for inducing apoptosis in imatinib mesylate refractory leukemia cells, the method comprising the steps of contacting the living cells with a compound comprising imatinib mesylate and suberoylanilide hydroxamic acid for about 48 hours;

wherein the compound has a concentration between about 1.0 uM and about 10.0 uM of imatinib mesylate and suberoylanilide hydroxamic acid.

18. (Previously Presented) A chemical composition for inducing apoptosis in cancer cells comprising between about 1.0 uM and about 10.0 uM of imatinib mesylate and suberoylanilide hydroxamic acid.

19. (New) A method for inducing apoptosis in cancer cells, the method comprising the steps of contacting the living cells with a tyrosine kinase inhibitor and a histone deacetylase inhibitor.

20. (New) The method of claim 19 wherein the tyrosine kinase inhibitor is imatinib mesylate.

21. (New) The method of claim 19 wherein the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.

22. (New) The method of claim 19 wherein the tyrosine kinase inhibitor is imatinib mesylate and the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.

23. (New) Method of claim 19 wherein the living cells are exposed to the tyrosine kinase inhibitor and the histone deacetylase inhibitor for about 48 hours.

24. (New) Method of claim 19 wherein the cancer cells are leukemia cells.

25. (New) Method of claim 19 wherein the cancer cells are imatinib mesylate refractory.